Zealand Pharma A/S (OTCMKTS:ZLDPF) Stock Price Up 4.3% - What's Next?

Key Points

• Zealand Pharma A/S shares rose by 4.3% to $57.40, but trading volume significantly decreased by 62% from the average.
• Analysts have upgraded the stock to a "strong-buy" rating, with six analysts currently issuing positive ratings, indicating strong confidence in the company's performance.
• Despite revenue of $1.43 billion, the company reported a loss in earnings per share, missing estimates and showing a negative return on equity of 13.40%.

Zealand Pharma A/S (OTCMKTS:ZLDPF - Get Free Report) shares rose 4.3% on Friday . The stock traded as high as $57.40 and last traded at $57.40. Approximately 348 shares traded hands during trading, a decline of 62% from the average daily volume of 917 shares. The stock had previously closed at $55.02.

Analyst Upgrades and Downgrades

ZLDPF has been the topic of several analyst reports. Wells Fargo & Company upgraded Zealand Pharma A/S to a "strong-buy" rating in a research report on Thursday, July 24th. BNP Paribas upgraded Zealand Pharma A/S to a "strong-buy" rating in a research report on Tuesday, July 1st. Zacks Research cut Zealand Pharma A/S from a "hold" rating to a "strong sell" rating in a research report on Friday, August 15th. Finally, Barclays upgraded Zealand Pharma A/S to a "strong-buy" rating in a research report on Monday, July 7th. Five analysts have rated the stock with a Strong Buy rating, one has issued a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, Zealand Pharma A/S presently has an average rating of "Buy".

Zealand Pharma A/S Stock Performance

The company's 50-day moving average price is $57.26 and its two-hundred day moving average price is $70.28. The stock has a market cap of $4.33 billion, a PE ratio of 4.28 and a beta of 0.71. The company has a debt-to-equity ratio of 0.03, a quick ratio of 25.07 and a current ratio of 25.10.

Zealand Pharma A/S (OTCMKTS:ZLDPF - Get Free Report) last released its earnings results on Thursday, August 14th. The company reported $16.06 EPS for the quarter, missing analysts' consensus estimates of $16.72 by ($0.66). Zealand Pharma A/S had a net margin of 73.90% and a return on equity of 82.30%. The firm had revenue of $1.43 billion during the quarter, compared to the consensus estimate of $9.18 billion. On average, equities research analysts forecast that Zealand Pharma A/S will post -2.19 EPS for the current year.

About Zealand Pharma A/S

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon.